Decreased CYP3A expression and activity in guinea pig models of diet-induced metabolic syndrome: Is fatty liver infiltration involved?

Drug Metabolism and Disposition

Volumn 41, Issue 5, 2013, Pages 952-957

  Simard, Chantale ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; DOMPERIDONE; DRUG METABOLITE; FATTY ACID; MESSENGER RNA; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET; DRUG METABOLISM; ENZYME ACTIVITY; FATTY LIVER; GENE EXPRESSION; GUINEA PIG; HIGH FRUCTOSE DIET; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH SUCROSE DIET; LIPID DIET; LIVER MICROSOME; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CYTOCHROME P-450 CYP3A; DISEASE MODELS, ANIMAL; FATTY LIVER; GUINEA PIGS; HUMANS; MALE; METABOLIC SYNDROME X; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

CAVIA;

EID: 84876765619     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050641     Document Type: Article

References (27)

1. Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, and Shader RI (1984) The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet 9: 177-183.
2. Aitken AE, Richardson TA, and Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149.
3. Bryant SM, Wan X, Shipsey SJ, and Hart G (1998) Regional differences in the delayed rectifier current (IKr and IKs) contribute to the differences in action potential duration in basal left ventricular myocytes in guinea-pig. Cardiovasc Res 40:322-331.
4. Caillier B, Pilote S, Patoine D, Levac X, Couture C, Daleau P, Simard C, and Drolet B (2012) Metabolic syndrome potentiates the cardiac action potential-prolonging action of drugs: A possible 'anti-proarrhythmic' role for amlodipine. Pharmacol Res 65:320-327.
5. Caraco Y, Zylber-Katz E, Berry EM, and Levy M (1995) Carbamazepine pharmacokinetics in obese and lean subjects. Ann Pharmacother 29:843-847.
6. Danielson PB (2002) The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 3:561-597.
7. Donato MT, Lahoz A, Jiménez N, Pérez G, Serralta A, Mir J, Castell JV, and Gómez-Lechón MJ (2006) Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 34:1556-1562.
8. Dostalek M, Court MH, Yan B, and Akhlaghi F (2011) Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 163:937-947.
9. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, and van Schaik RH (2011) A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 57:1574-1583.
10. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, and Cherrington NJ (2009) Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37:2087-2094.
11. Ghose R, Omoluabi O, Gandhi A, Shah P, Strohacker K, Carpenter KC, McFarlin B, and Guo T (2011) Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci 89:57-64.
12. Inaba T and Kovacs J (1989) Haloperidol reductase in human and guinea pig livers. Drug Metab Dispos 17:330-333.
13. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
14. Leclercq I, Horsmans Y, Desager JP, Delzenne N, and Geubel AP (1998) Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 28:410-416.
15. McCullough AJ (2002) Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 34: 255-262.
16. Moretto M, Kupski C, Mottin CC, Repetto G, Garcia Toneto M, Rizzolli J, Berleze D, de Souza Brito CL, Casagrande D, and Colossi F (2003) Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg 13: 622-624.
17. Mori T, Itoh S, Ohgiya S, Ishizaki K, and Kamataki T (1997) Regulation of CYP1A and CYP3A mRNAs by ascorbic acid in guinea pigs. Arch Biochem Biophys 348:268-277.
18. NCEPNational Cholesterol Education Program] (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421.
19. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, and Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555.
20. Patoine D, Mercier P, Pilote S, Petit M, Drolet B, and Simard C (2012) Type II diabetes decreases hepatic CYP3a expression in mouse. Clin Pharmacol Ther 91 (Suppl 1):S77.
21. Simard C, Michaud V, Gibbs B, Massé R, Lessard E, and Turgeon J (2004) Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 34: 1013-1023.
22. Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W, Grivennikov S, Wynshaw-Boris A, Scadeng M, and Olefsky JM, et al. (2007) JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 6:386-397.
23. Takahashi Y, Soejima Y, and Fukusato T (2012) Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 18:2300-2308.
24. Vandesompele J, De PK, Pattyn F, Poppe B, Van RN, De PA, and Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034.
25. West KL and Fernandez ML (2004) Guinea pigs as models to study the hypocholesterolemic effects of drugs. Cardiovasc Drug Rev 22:55-70.
26. Whiting DR, Guariguata L, Weil C, and Shaw J (2011) IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311-321.
27. Yoshinari K, Takagi S, Yoshimasa T, Sugatani J, and Miwa M (2006) Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm Res 23:1188-1200.